We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Cell Fitness Status Detected from Nasal Swab Test Could Accurately Predict Hospitalization or Death in COVID-19 Patients

By LabMedica International staff writers
Posted on 19 Oct 2021

In the future, billions of COVID-19 nasal swab tests could not only tell if you have contracted COVID-19, but maybe even foretell if you are in danger of a serious infection. More...

In a new study, researchers from University of Copenhagen (Copenhagen, Denmark) have shown that the phenomenon cell fitness could predict the host immune response to a COVID-19-infection. The study has shown that analysis of a particular protein on the cell surface is likely to predict who is in danger of a serious infection caused by the virus. The discovery could prove to be important for pandemic management.

“Cells have a so-called fitness status, and by analyzing it we could predict hospitalization or death in COVID-19 patients, potentially making such a biomarker an earlier prediction tool, especially because it can be detected from the common nasal swab COVID-19-tests,” said Rajan Gogna from the Won Group at the Biotech Research & Innovation Centre.

If the cell fitness status is poor, it indicates that the cell does not develop well, either because the cell is aged, lacks reliability, has an ill-functioning metabolism or is disease prone etc. Earlier in 2021, the research team discovered that fitness status is expressed in proteins called flower proteins. These flower proteins are on the surface of the cell, and they are expressed in two forms, explained Gogna. Especially helpful in cases of the early phase of COVID-19 illness, the flower protein expression could accurately predict hospitalization or death as well predict who would have a less serious infection.

Cell fitness is relative to many things in our bodies and does not necessarily alter with age. Age has an impact, but the researchers have seen many cases from their database where people who are 80 years of age have a very good fitness profile of lungs, which is the main area where cell fitness is measured to predict COVID-19 infection outcome, explained Gogna. The researchers performed a post-mortem examination of the infected lung tissue in deceased COVID-19 patients to determine the flower proteins biological role in acute lung injury, which is the main cause of death from the disease. By using nasal swab samples, they also performed an observational study to evaluate whether the protein expression could accurately predict hospitalization or death.

“The method could predict who needed hospitalization with an accuracy of was 78.7%. With COVID-19 patients who would not have a serious infection, the prediction was accurate at 93.9%,” said Associate Professor and Group Leader Kyoung Jae Won, who analyzed the data using machine learning.

As parts of the Western world is slowly returning to normal, many countries in the low- and middle-income countries are still fighting and fearing new outbreaks of COVID-19. And for most it feels almost unbearable to endure another new wave of the virus, which could end in more deaths and long-term persistent symptoms from COVID-19 infection. The researchers hope their discovery is timely, because of the persistency of COVID-19 and rising cases and deaths in various nations outside the Western world despite vaccines.

“The cell fitness, expressed by the flower protein, could help explain why some people respond poorly to COVID-19 and provide opportunity for pre-identification of high-risk individuals. This discovery has the potential to help save their lives by severely alerting them to be extra protective of themselves, or until they are fortunate enough to get their hands on a vaccine. In some other nations, the population in general has great hesitancy against vaccination. But people are not hesitant about a test, and we hope this will improve outcomes,” added Gogna.

Related Links:
University of Copenhagen 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.